Gilead Sciences Stock Analysis, Valuation (NASDAQ:GILD)

Add to My Stocks
$72.48 $0.5 (0.69%) GILD stock closing price Dec 28, 2017 (Closing)
Watch Robo Advisor Video of GILD Stock Analysis
Gilead Sciences
Updated on : Dec 28, 2017
previous close
GILD 72.5 (0%)
S&P 500 2687.5 (0%)
Closing Price On: Dec 28, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Dividend Yield
GILD dividend yield:
Operating Margins
Net Margins
FCF Margin
PE Valuation
Recent Growth
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector: Medical. *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Gilead Sciences Stock Analysis

7119 10 3

Investors can watch the waldorf-kras Gilead Sciences stock analysis video here. This video puts forward our latest analysis highlighting the pros and cons for GILD stock.

Gilead Sciences, Inc. Stock Rating 4.3/5

waldorf-kras GILD stock analysis takes into account various financial ratios like relative valuation, Gilead Sciences revenue, growth and return on equity based on latest quarter 2017 Q3 financial statements. We also check Gilead Sciences dividend performance. Gilead Sciences valuation forms a crucial part of our stock analysis. Our Gilead Sciences stock rating is based on company's fundamentals like balance sheet risk and cash flow position.

Should you buy GILD stock?

  • Gilead Sciences's average operating margin of 57.8% was exceptional.
  • LTM Net margins were good at 42.2% for Gilead Sciences.
  • The price to earnings multiple of 7.6 is attractive when compared with the industry average PE ratio of 23.7.
  • GILD stock is trading at a favorable price to sales multiple of 3.4 as against the Medical-Biomed-Genetics industry average multiple of 5.7.
  • Gilead Sciences generates a high return on invested capital of 44.7%.
  • Gilead Sciences has a good Return On Equity (ROE) of 54.7%.
  • The company has a healthy free cash flow margin of 39.4%.

Should you sell GILD stock?

  • Gilead Sciences revenue saw a decline of -13.2% YoY in 2017 Q3.
  • Gilead Sciences is debt laden and has a high debt/equity ratio of 1.25.

Comments on this video and Gilead Sciences stock

Investors can use waldorf-kras Gilead Sciences stock analysis as a tool to arrive at conclusions regarding financial health of the company and its valuation. Fundamental analysis of a company is the most often used approach to find the intrinsic value of a stock.

Among the financials of the company, Gilead Sciences revenue growth along with the profit or net income give a clear picture of the financial health. Investors could make use of GILD technical analysis to check whether the fundamental story is reflected in the market sentiment.